Actively Recruiting
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Led by Dartmouth-Hitchcock Medical Center · Updated on 2026-02-12
62
Participants Needed
1
Research Sites
93 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called aromatase; aromatase changes other hormones in the body to estrogen. Women who do not complete the standard 5-year treatment are at higher risk of their cancer coming back. The goal of this research is to prevent breast cancer from coming back after surgery by helping women to stay on treatment with aromatase inhibitors. Researchers believe the best path to help women to stay on treatment is to create a better way to manage (control) side effects.
CONDITIONS
Official Title
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologic confirmation of DCIS or invasive breast cancer by biopsy
- Estrogen receptor alpha (ER)-positive DCIS or invasive cancer
- HER2-negative invasive cancer (IHC 0-1+ or FISH ratio <1.8 if IHC 2+ or not done)
- Clinical Stage I-III invasive breast cancer or DCIS
- Clinically indicated for adjuvant treatment with letrozole, anastrozole, or exemestane
- Plan to continue adjuvant endocrine therapy for at least 2 years at registration
- Women aged over 18 years who are post-menopausal (last menstrual period >2 years ago or >1 year with post-menopausal hormone levels)
- Meet clinical lab criteria: ANC >1,000/mm3, platelet count >75,000/mm3, bilirubin <1.5x ULN, ALT and AST <3x ULN
- Able to give informed consent
You will not qualify if you...
- Prior endocrine therapy for any confirmed cancer or breast cancer prevention in last 10 years
- Any other adjuvant therapy for breast cancer except bisphosphonates or denosumab for bone issues
- Prescribed tamoxifen as first endocrine therapy instead of an aromatase inhibitor
- Pregnant or lactating women
- Prisoners
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dartmouth Cancer Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
Research Team
K
Kristina M. Willey
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here